Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?

被引：4

作者：

Kassimis, George ^{[1
]}

Stavrou, Eleana F. ^{[2
]}

Alexopoulos, Dimitrios ^{[1
]}

Athanassiadou, Aglaia ^{[2
]}

机构：

[1] Patras Univ Hosp, Dept Cardiol, Patras 26500, Greece

[2] Univ Patras, Sch Med, Lab Gen Biol, GR-26110 Patras, Greece

来源：

CURRENT PHARMACEUTICAL DESIGN | 2013年 / 19卷 / 13期

关键词：

Clopidogrel; prasugrel; ticagrelor; percutaneous coronary intervention; CYP2C19; polymorphism; CLOPIDOGREL PLATELET REACTIVITY; CORONARY-ARTERY-DISEASE; PROTON PUMP INHIBITORS; OF-FUNCTION POLYMORPHISM; MAINTENANCE-DOSE CLOPIDOGREL; ACUTE MYOCARDIAL-INFARCTION; ADVERSE CLINICAL-OUTCOMES; CALCIUM-CHANNEL BLOCKERS; ASPIRIN-TREATED PATIENTS; TIMI; 38; TRIAL;

D O I：

10.2174/1381612811319130017

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among those undergoing percutaneous coronary intervention. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently in the daily clinical practice with better cardiovascular outcome in these patients. The purpose of this review article is to provide information regarding the clinical use of CYP2C19 genotyping in patients requiring antiplatelet therapy.

引用

页码：2489 / 2495

页数：7

共 50 条

[21] Relationship between recurrent ischemic events in cerebrovascular disease and cytochrome P450 2C19 gene polymorphism on the basis of thrombelastography [J].

Liu, Jiaming ;

Zhao, Yulong ;

Chen, He ;

Yang, Fangyu ;

Chen, Ligang ;

Hao, Guangzhi ;

Gao, Xu .

ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (01) :240-249

[22] The Pharmacogenetics of Cytochrome P450 2C19 enzymes - Effects on Clopidogrel and Proton Pump Inhibitors [J].

Liau, Yusmiati ;

Muliaty, Dewi .

INDONESIAN BIOMEDICAL JOURNAL, 2014, 6 (01) :33-44

[23] Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis [J].

Hou, Xiaowen ;

Shi, Jingpu ;

Sun, Hao .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) :1041-1047

[24] Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis [J].

F Sofi ;

B Giusti ;

R Marcucci ;

A M Gori ;

R Abbate ;

G F Gensini .

The Pharmacogenomics Journal, 2011, 11 :199-206

[25] Serum interleukin-18 levels as a predictor for patients with genetic dysfunction of cytochrome P450 2C19 in dual antiplatelet therapy with clopidogrel [J].

Ishimatsu, Takashi ;

Sasaki, Ken-ichiro ;

Kakuma, Tatsuyuki ;

Harada, Atsushi ;

Hirakawa, Yuji ;

Fukumoto, Yoshihiro ;

Ueno, Takafumi .

JOURNAL OF CARDIOLOGY, 2020, 76 (05) :479-486

[26] In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants [J].

Nakanishi, Kazuyuki ;

Uehara, Shotaro ;

Kusama, Takashi ;

Inoue, Takashi ;

Shimura, Kanami ;

Kamiya, Yusuke ;

Murayama, Norie ;

Shimizu, Makiko ;

Uno, Yasuhiro ;

Sasaki, Erika ;

Yamazaki, Hiroshi .

BIOCHEMICAL PHARMACOLOGY, 2018, 152 :272-278

[27] Association of Cytochrome P450 2C19 Polymorphism With Ischemic and Bleeding Risk in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention [J].

Gjermeni, Diona ;

Szabo, Sofia ;

Anfang, Viktoria ;

Vetter, Hannah ;

Hesselbarth, David ;

Leggewie, Stefan ;

Trenk, Dietmar ;

Duerschmied, Daniel ;

Westermann, Dirk ;

Olivier, Christoph B. .

CIRCULATION, 2023, 148

[28] Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention [J].

Sibbing, Dirk ;

Stegherr, Julia ;

Latz, Wolfgang ;

Koch, Werner ;

Mehilli, Julinda ;

Doerrler, Katharina ;

Morath, Tanja ;

Schoemig, Albert ;

Kastrati, Adnan ;

von Beckerath, Nicolas .

EUROPEAN HEART JOURNAL, 2009, 30 (08) :916-922

[29] Efficacy and Adverse Events of Clopidogrel and Ticagrelor in Patients with Cytochrome P450 2C19 Gene Deletion [J].

Cai, Xiaofang ;

Jiang, S. J. ;

Chen, Jiana ;

Cai, Xiujuan ;

Wang, W. L. ;

Huang, J. D. ;

Zhang, J. H. .

INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 :175-181

[30] Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy [J].

Attia, Tamer Z. ;

Yamashita, Taku ;

Tsujino, Hirofumi ;

Derayea, Sayed M. ;

Tsutsumi, Yasuo ;

Uno, Tadayuki .

CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (08) :810-815

← 1 2 3 4 5 →